玻璃体腔注射康柏西普联合全视网膜光凝治疗进展型糖尿病性视网膜病变的效果观察

doi:10.3969/j.issn.1006-6233.2018.08.021

摘要
图/表
参考文献
相关文章 (1)

全文: PDF (1333 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨玻璃体腔注射康柏西普联合全视网膜光凝治疗对进展型糖尿病性视网膜病变(DR)患者视神经纤维层(RNFL)厚度、黄斑厚度及视力的影响。 方法: 进展型DR患者76例,随机分为实验组和对照组,各38例。实验组给予玻璃体腔注射康柏西普联合全视网膜光凝治疗,对照组仅给予全视网膜光凝治疗。治疗前、后均通过相关检查获取RNFL厚度及黄斑厚度,检测血清血管内皮生长因子(VEGF)浓度,评估视力恢复效果及统计并发症发生情况。 结果: 两组治疗前RNFL厚度及黄斑厚度比较无统计学意义(P>0.05),治疗后均显著降低,且实验组视盘上方、下方、颞侧、鼻侧环状区平均RNFL厚度、全周360°RNFL厚度以及黄斑厚度均显著低于对照组,差异有统计学意义(P<0.05)。两组治疗前血清VEGF浓度、BCVA比较无统计学意义(P>0.05),但与对照组相比,实验组治疗后7、14、28d各时间点血清VEGF浓度显著低,BCVA增高幅度明显大,差异有统计学意义(P<0.05)。实验组治疗后前房炎性反应、高眼压、角膜水肿、新生血管增生发生率均略低于对照组,但差异无统计学意义(P>0.05)。 结论: 全视网膜光凝治疗前给予玻璃体腔注射康柏西普有助于降低进展型DR患者RNFL厚度、黄斑厚度及血清VEGF浓度,从而显著改善视力。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	常艳

关键词 ：玻璃体腔, 康柏西普, 全视网膜光凝, 进展型, 糖尿病性视网膜病变

Abstract：Objective: To investigate the effect of intravitreal injection of Conbercept combined with panretinal photocoagulation on the thickness of retinal nerve fiber layer (RNFL), macular thickness and visual acuity in patients with progressive diabetic retinopathy (DR). Methods: 76 patients with progressive DR were randomly divided into the experimental group and the control group, with 38 cases in each group. The former was treated by intravitreal injection of Conbercept combined with panretinal photocoagulation, while the latter was only treated with panretinal photocoagulation alone. The thickness of RNFL and macular thickness were obtained through related examinations before and after treatment. The concentration of serum vascular endothelial growth factor (VEGF) was detected, the recovery of visual acuity was evaluated, and the incidence of complications was statistically analyzed. Results: There was no significant difference in the thickness of RNFL and macular thickness between the two groups before treatment (P>0.05). However, the thickness of RNFL and macular thickness were significantly decreased after the treatment, and the average RNFL thickness of the upper, lower, temporal and nasal side ring area of the optic disc, the thickness of whole-cycle 360 degrees RNFL and macular thickness in the experimental group were significantly lower than those in the control group (P<0.05). There was no significant difference in the concentration of serum VEGF and the BCVA between the two groups before treatment (P>0.05). The concentration of serum VEGF in at the experimental group at 7d, 14d and 28d after treatment was significantly lower than that in the control group, and the increase of the BCVA was significantly greater than that in the control group (P<0.05). The incidence rates of anterior chamber inflammatory reactions, intraocular hypertension, corneal edema and neovascularization in the experimental group after treatment were slightly lower than those in the control group (P>0.05). Conclusion: Intravitreal injection of compaitcp before retinal photocoagulation helps to reduce the thickness of RNFL, macular thickness and serum VEGF concentration in progressive DR patients, thus improving visual acuity.

Key words： Vitreous cavity Conbercept Total retinal Progressive Diabetic retinopathy

基金资助:新疆维吾尔自治区自然科学基金,(编号:20161C2517)

引用本文:

常艳. 玻璃体腔注射康柏西普联合全视网膜光凝治疗进展型糖尿病性视网膜病变的效果观察[J]. 河北医学, 2018, 24(8): 1310-1314.
CHANG Yan. Effect Observation of Vitreous Injection of Compaq combined with Total Retinal Photocoagulation on Progressive Diabetic Retinopathy. HeBei Med, 2018, 24(8): 1310-1314.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2018.08.021 或 http://www.hbyxzzs.cn/CN/Y2018/V24/I8/1310

[1] 曾凯宏,王元,邓波,等.糖尿病早期大鼠视网膜功能损伤及白藜芦醇防护作用研究[J].成都医学院学报,2016,11(5):523~527.
[2] 陈静,王继红.改良全视网膜光凝顺序治疗对重度非增殖期糖尿病性视网膜病变患者黄斑厚度及视力改善的效果[J].中国临床研究,2017,30(1):120~122.
[3] 郭婧,陈松,何广辉,等.内界膜剥除联合或不联合玻璃体腔注射康柏西普治疗顽固性糖尿病黄斑水肿的疗效对比观察[J].临床眼科杂志,2017,25(3):219~222.
[4] 尹妮,赵帅,朱红娜.康柏西普预处理联合玻璃体切割术治疗增生型糖尿病视网膜病变[J].眼科新进展,2017,37(8):770~772.
[5] Wei YM,Yan J,Yang HX.Identification of severe gestational diabetes mellitus after new criteria used in China[J].Perinatol,2016,36(2):90~94.
[6] 刘三梅,李杰,董文韬,等.玻璃体腔内注射康柏西普联合视网膜光凝治疗增生性糖尿病视网膜病变的中长期临床观察[J].成都中医药大学学报,2017,40(1):63~65.
[7] 韩月圣,魏文斌.Ranibizumab玻璃体腔注射后糖尿病黄斑水肿患者中心视网膜厚度相对变化与视力预后的关系[J].中华实验眼科杂志,2016,34(1):78~84.
[8] 罗娜,LUONa.视网膜光凝联合康柏西普玻璃体内注射治疗糖尿病视网膜病变的RNFL厚度、血清细胞因子含量评估[J].海南医学院学报,2016,22(16):1904~1907.
[9] 王海山,张海军,崔龙江,等.改良全视网膜光凝顺序对重度非增殖期糖尿病性视网膜病变患者中心视力和黄斑厚度的影响[J].中国实用眼科杂志,2016,34(2):109~113.
[10] Erie J C,Barkmeier A J,Hodge D O,et al.High variation of intravitreal injection rates and medicare anti-vascular endothelial growth factor payments per injection in the united states.[J].Ophthalmology,2016,123(6):1257~1262.
[11] 朱涛,马勇.玻璃体腔注射康柏西普对糖尿病视网膜病变的疗效[J].西南国防医药,2016,26(10):1121~1123.
[12] 范金连,曾琦,段国平.玻璃体内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的临床研究[J].医学临床研究,2016,33(1):83~85.
[13] 刘萱,王妮,仲萌睿,等.康柏西普球内注射治疗脉络膜新生血管的临床疗效观察[J].西南国防医药,2017,27(1):43~45.
[14] 奚翠萍,范寒桂.抗血管内皮生长因子药物联合激光光凝治疗糖尿病性黄斑水肿临床观察[J].武汉大学学报(医学版),2017,38(5):794~795.
[15] 闫忠阳,冬敏,杨娜,等.康柏西普玻璃体腔注射治疗糖尿病视网膜病变伴黄斑水肿的临床效果[J].山东医药,2017,57(37):57~59.
[16] 杨喆,相义会,付颖.康柏西普玻璃体内注射联合眼底激光光凝治疗对糖尿病性黄斑水肿患者视力及黄斑中心厚度的影响[J].西北国防医学杂志,2017,38(1):19~22.
[17] 韩姬,王玲,刘伟仙,等.康柏西普玻璃体腔注射对糖尿病视网膜病变患者视力的影响[J].中国全科医学,2015,18(5):502~506.